<?xml version="1.0" encoding="UTF-8"?>	<item><status>past</status><description>&lt;p&gt;&lt;span&gt;January 19, 2012 &lt;br /&gt;

Thursday&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;5:30-8:30pm&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;Genzyme Corporation &lt;br /&gt;

500 Kendall Street&lt;/span&gt; &lt;span&gt;Cambridge, MA 02142&lt;/span&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt;
&lt;p style="color : #00268d"&gt;$35 - Professionals in biotech/pharma companies and academia&lt;/p&gt;
&lt;p style="color : #00268d"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="color : #00268d"&gt;$50.00 - Service providers&lt;/p&gt;
&lt;p style="color : #00268d"&gt;&lt;a href="http://tbnpatentreform.eventbrite.com/"&gt;http://tbnpatentreform.eventbrite.com/&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;On September 16, President Obama signed into law the &lt;em&gt;America Invents Act&lt;/em&gt;, the first significant change to patent law since 1952. The two major provisions of the law are the shift from a "first to invent" system to one aligned with patent law in the rest of the world based on "first to file," and provisions for a "post grant review period" designed to address bad patents.&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&lt;span&gt;Will the new law have as critical an impact, good or bad? Will it fundamentally change deal making in the life sciences? What is the impact on inventors? Attendees will have a chance to hear about these issues and interact with the panel.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style="text-decoration : underline"&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt; &lt;br /&gt;

5:30-6:30pm: Refreshments &lt;span&gt;and Networking&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;6:30-8:00pm: Panel Discussion&lt;/p&gt;
&lt;p&gt;8:00-8:30pm: Networking&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="text-decoration : underline"&gt;&lt;strong&gt;Panel&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;span style="color : #000066"&gt;&lt;span style="text-decoration : underline"&gt;Moderator:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&lt;em&gt;Jennifer Lacroix&lt;/em&gt;, Partner, DLA Piper US LLP&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style="text-decoration : underline"&gt;Panelists:&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&lt;em&gt;Todd Foley&lt;/em&gt;, Managing Director, MPM Capital&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span&gt;&lt;em&gt;Irena Melnikova&lt;/em&gt;, PhD, Director, Prospective and Strategic Initiatives, Sanofi&lt;/span&gt; &lt;br /&gt;

&lt;em&gt;Christopher K. Mirabelli&lt;/em&gt;, Ph.D., Partner, HealthCare Ventures &lt;br /&gt;

&lt;em&gt;Lita Nelsen&lt;/em&gt;, Director, Technology Licensing Office, Massachusetts Institute of Technology&lt;/p&gt;
&lt;p&gt; &lt;br /&gt;

 &lt;br /&gt;

&lt;/p&gt;</description><event_hosts><event_hosts_item><member_name>Joshua Lang</member_name><member_id>3926861</member_id></event_hosts_item></event_hosts><maybe_rsvp_count>0</maybe_rsvp_count><waitlist_count>0</waitlist_count><updated>1327017161000</updated><rating><average>0.0</average><count>0</count></rating><group><who>Scientific Members</who><join_mode>open</join_mode><urlname>nexusproject</urlname><id>1294865</id><group_lat>42.3699989319</group_lat><group_lon>-71.0999984741</group_lon><name>Nexus Project</name></group><yes_rsvp_count>2</yes_rsvp_count><created>1325812003000</created><visibility>public</visibility><name>Impact of the America Invents Act on deal making in the life sciences industry</name><id>46877632</id><headcount>0</headcount><utc_offset>-18000000</utc_offset><time>1327012200000</time><event_url>http://www.meetup.com/nexusproject/events/46877632/</event_url></item>